Evaluation the influence of sex hormones concentration in pre- and postmenopausal women;Ocena wpływu wybranych hormonów na stȩżenie homocysteiny u kobiet przed menopauza̧ i po menopauzie

Polski Merkuriusz Lekarski

Volumn 18, Issue 104, 2005, Pages 189-191

  Bednarek Tupikowska, Grazyna ^a   Tupikowski, Krzysztof ^a   Bohdanowicz Pawlak, Anna ^a   Bidzińska, Bozena ^a   Szymczak, Jadwiga ^a   Filus, Alicja ^a   Kuliczkowska, Justyna ^a   Milewicz, Andrzej ^a  

^a Katedra i Klinika Endokrynologii   (Poland)

Author keywords

Homocysteine; Menopause; Sex hormones

Indexed keywords

ESTRADIOL; ESTROGEN; FOLLITROPIN; HOMOCYSTEINE; HYDROCORTISONE; PRASTERONE SULFATE; PROGESTERONE; SEX HORMONE; TESTOSTERONE;

ADULT; AMINO ACID BLOOD LEVEL; ARTICLE; CORRELATION ANALYSIS; ESTROGEN ACTIVITY; ESTROGEN THERAPY; FEMALE; HORMONE BLOOD LEVEL; HUMAN; HYPOTHESIS; MAJOR CLINICAL STUDY; MENOPAUSE; POSTMENOPAUSE; PREMENOPAUSE;

DEHYDROEPIANDROSTERONE SULFATE; ESTROGEN REPLACEMENT THERAPY; ESTROGENS; FOLLICLE STIMULATING HORMONE; GONADAL STEROID HORMONES; HOMOCYSTEINE; HUMANS; HYDROCORTISONE; HYPERHOMOCYSTEINEMIA; MALE; MIDDLE AGED; POSTMENOPAUSE; PREMENOPAUSE; PROGESTERONE; TESTOSTERONE;

EID: 14644396516     PISSN: 14269686     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. Anderson A. i wsp.: Plasma homocysteine before and after methionine loadnig with regard to age, gender and menopausal status. Eur. J. Clin. Invest., 1992, 22, 79-87.
2. Bednarek-Tupikowska G.: Wpływ estradiolu na wybrane parametry systemu antyoksydacyjnego i niektóre czynniki ryzyka miażdżycy u kobiet po menopauzie. Akademia Medyczna, Wrocław 2002.
3. Boushey C.J. i wsp.: A quantitative assesment of plasma homocysteine as risk factor for vascular disease - probable benefits of increasing folic acid intakes. JAMA, 1995, 274, 1049-1057.
4. Christodoulakos G. i wsp.: Homocysteine and folate levels in postmenopausal women. Maturitas, 2001, 39, 161-167.
5. Domagala B. i wsp.: Hiperhomocysteinemia i jej zwia̧zek z miażdżyca̧ tȩtnic. Pol. Arch. Med. Wew., 1997, 98, 153-162.
6. Grady D. i wsp.: Cardiovascular disease potcomes during 6.8 years of hormone therapy. Heart and Estrogen/progestln Replacement Study Follow-up (HERS II). JAMA, 2002, 288, 1, 49-57.
7. Graham I.M. i wsp.: Plasma homocysteine as risk factor for vascular disease: the European Concerted Action Project. JAMA, 1997, 277, 1775-1781.
8. Hulley S. i wsp.: Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. JAMA, 1998, 280, 605-613.
9. Kang S.S. i wsp.: Proteinbound homocysteine. A possible risk factor for coronary artery disease. J. Clin. Invest., 1986, 77, 1482-1486.
10. Mijatovic V. i wsp.: Postmenopausal oral 17-β-estradiol continuously combined with dydrogesterone reduces fasting serum homocysteine levels. Fertil. Steril., 1998, 69, 876-882.
11. Moustapha A., Robinson K.: Homocysteine: an emerging age-related cardiovascular risk factor. Geriatrics, 1999, 54, 49-63.
12. Piechota W.: Homocysteina nowy czynnik ryzyka chorób układu kra̧żenia. ABBOTT Laboratories Poland Sp. z o.o., Warszawa 1998.
13. Rasmussen K. i wsp.: Age- and gender-specyfic reference intervals for total homocysteine and methylmalonic acid in plasma before and after vitamin supplementation. Clin. Chem., 1996, 42, 630-636.
14. Stampfer M.J. i wsp.: A prospective study of plasma homocyst(e)ine and risk of myocardial infarction in US physicians. JAMA, 1992, 268, 877-881.
15. Van der Mooren M.J. i wsp.: Homocysteine concentrations may decrease during postmenopausal hormone repalcement therapy. Ir. J. Med. Sci., 1995, 164 (supl. 15), 21.
16. Walsh B.W. i wsp.: The effects of hormone replacement therapy and raloxifene on C-reactive protein and homocysteine in healthy postmenopausal women: a randomized, controlled trial. J. Clin. Endocrinol. Metab., 2000, 85, 214-218.
17. Wouters M.G.A.J.: Plasma homocysteine and menopausal status. Eur. J. Clin. Invest., 1995, 25, 801-805.
18. Writing Group for the Women's Health Intiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women. JAMA, 2002, 288 (3), 321-333.